MANGROVE PARTNERS IM, LLC

Holdings History for Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)

Symbol: ANEB on OTC
Investment type: Equity / Common Stock
Latest Disclosed Shares Owned: 2,525,252 shares
Security Ownership %: 6.2%

Shares, Excluding Options vs Price

Value, Excluding Options

Mangrove Partners IM, LLC ownership in Anebulo Pharmaceuticals, Inc. Common Stock (ANEB)

17 Mar 2025 - Mangrove Partners IM, LLC has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,525,252 shares of Anebulo Pharmaceuticals, Inc. Common Stock (ANEB). This represents 6.2% ownership of the company. This is the first filing by MANGROVE PARTNERS IM, LLC disclosing ownership of Anebulo Pharmaceuticals, Inc. Common Stock (ANEB).

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filing time
Mangrove Partners IM, LLC	6.2%		$2,979,797	2,525,252			$1.18	13G	31 Dec 2024	17 Mar 2025, 16:51

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
31 Dec 2025	0.21%	0%	$2,550,505	2,525,252	0		$1.01	Q4 2025
30 Sep 2025	0.47%	0%	$6,313,130	2,525,252	0		$2.50	Q3 2025
30 Jun 2025	0.39%	0%	$3,636,363	2,525,252	0		$1.44	Q2 2025
31 Mar 2025	0.37%	0%	$3,282,828	2,525,252	0		$1.30	Q1 2025
31 Dec 2024	0.43%	+0.43%	$3,635,757	2,525,252	+2,525,252	NEW	$1.44	Q4 2024
31 Dec 2023		-0.12%	$0	0	-399,219	-100%	$0.47	Q4 2023
30 Sep 2023	0.12%	0%	$1,219,614	399,219	0		$3.05	Q3 2023
30 Jun 2023	0.09%	0%	$938,165	399,219	0		$2.35	Q2 2023
31 Mar 2023	0.12%	0%	$1,157,735	399,219	0		$2.90	Q1 2023
31 Dec 2022	0.09%	0%	$967,587	399,219	0		$2.42	Q4 2022
30 Sep 2022	0.1%	0%	$1,118,000	399,219	0		$2.80	Q3 2022
30 Jun 2022	0.16%	0%	$2,076,000	399,219	0		$5.20	Q2 2022
31 Mar 2022	0.22%	-0%	$2,826,000	399,219	-7,840	-1.9%	$7.08	Q1 2022
31 Dec 2021	0.19%	-0%	$2,503,000	407,059	-9,487	-2.3%	$6.15	Q4 2021
30 Sep 2021	0.3%	-0.01%	$2,728,000	416,546	-11,954	-2.8%	$6.55	Q3 2021
30 Jun 2021	0.32%	+0.32%	$2,922,000	428,500	+428,500	NEW	$6.82	Q2 2021

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.